Clinical

Dataset Information

0

OSI-906 and Irinotecan in Patients With Advanced Cancer

ABSTRACT: This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S. government agency that reviews the results of research of drugs and decides if it can be sold in the U.S. OSI-906 has been given to over 185 people with cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2081035 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Study of Intermittent OSI-906 Dosing
| 2043067 | ecrin-mdr-crc
Clinical A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva)
| 2060049 | ecrin-mdr-crc
Clinical Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
| 2091466 | ecrin-mdr-crc
Unknown Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
| S-EPMC8197973 | biostudies-literature
Unknown A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
| S-EPMC5061534 | biostudies-literature
Unknown Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
| S-EPMC7856429 | biostudies-literature
Unknown Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines.
| S-EPMC7763458 | biostudies-literature
Clinical Study of Continuous OSI-906 Dosing
| 2043046 | ecrin-mdr-crc
Clinical OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer
| 2010685 | ecrin-mdr-crc
Clinical Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
| 2049746 | ecrin-mdr-crc